Source: Medicines & Healthcare Products Regulatory Agency (GB) Revision Year: 2023 Publisher: Mercury Pharmaceuticals Limited, Dashwood House, 69 Old Broad Street, London, EC2M 1QS, United Kingdom
Dopamine Hydrochloride 40mg/ml Concentrate for Solution for Infusion.
Pharmaceutical Form |
---|
Concentrate for solution for infusion. Clear, colourless or pale yellow solution. |
Each ml contains 40 mg dopamine hydrochloride.
Each 5 ml ampoule contains 200mg Dopamine hydrochloride
Excipient(s) with known effect:
Each 5mL ampoule contains 50 mg sodium metabisulfite.
For the full list of excipients, see section 6.1.
Active Ingredient | Description | |
---|---|---|
Dopamine |
Dopamine hydrochloride stimulates adrenergic receptors of the sympathetic nervous system. Dopamine hydrochloride has principally a direct stimulatory effect on β1-adrenergic receptors, but also appears to have an indirect effect by releasing norepinephrine from its storage sites. Dopamine hydrochloride also appears to act on specific dopaminergic receptors in the renal, mesenteric, coronary, and intracerebral vascular beds to cause vasodilation. |
List of Excipients |
---|
Sodium metabisulfite (E223) |
5 ml clear glass one point-cut (OPC) ampoules, glass Type I Ph Eur. borosilicate glass ampoules packed in cardboard cartons to contain 10 × 5ml ampoules.
Mercury Pharmaceuticals Limited, Dashwood House, 69 Old Broad Street, London, EC2M 1QS, United Kingdom
PL 12762/0571
Date of first authorisation: 14 September 1989
Date of latest renewal: 19 March 2008
Drug | Countries | |
---|---|---|
DOPAMINE | Nigeria |
© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.